151 related articles for article (PubMed ID: 35674245)
1. Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access.
Martin MT; Waring N; Forrest J; Nazari JL; Abdelaziz AI; Lee TA
Public Health Rep; 2023; 138(3):467-474. PubMed ID: 35674245
[TBL] [Abstract][Full Text] [Related]
2. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020.
Beiser ME; Shaw LC; Wilson GA; Muse KO; Shores SK; Baggett TP
J Gen Intern Med; 2023 Mar; 38(4):865-872. PubMed ID: 36127534
[TBL] [Abstract][Full Text] [Related]
4. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.
Cartwright EJ; Pierret C; Minassian C; Esserman DA; Tate JP; Goetz MB; Bhattacharya D; Fiellin DA; Justice AC; Lo Re V; Rentsch CT
JAMA Netw Open; 2023 Sep; 6(9):e2335715. PubMed ID: 37751206
[TBL] [Abstract][Full Text] [Related]
5. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
6. Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response.
Liu A; Angirekula M; Elhawary A; Mara K; Kulai T; Leise M; Watt KD
Clin Transplant; 2023 Oct; 37(10):e15050. PubMed ID: 37329298
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
[TBL] [Abstract][Full Text] [Related]
11. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
12. Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City.
Ziff J; Vu T; Dvir D; Riazi F; Toribio W; Oster S; Sigel K; Weiss J
Harm Reduct J; 2021 Mar; 18(1):38. PubMed ID: 33789691
[TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
14. Sustained virologic response from hepatitis C from an emergency department screening & linkage program: A retrospective review.
Walter LA; Wilson L; Farmer M; Roberson T; Hand DT; Franco R
Am J Emerg Med; 2023 Oct; 72():178-182. PubMed ID: 37540919
[TBL] [Abstract][Full Text] [Related]
15. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar.
Min Thaung Y; Chasela CS; Chew KW; Minior T; Lwin AA; Sein YY; Drame N; Marange F; van der Horst C; Thwin HT; Freiman MJ; Gandhi MM; Bijl M; Wose Kinge C; Rosen S; Thura S; Mohamed S; Xulu T; Naing AY; Barralon M; Cavenaugh C; Kyi KP; Sanne I;
J Viral Hepat; 2021 Jan; 28(1):147-158. PubMed ID: 32935438
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
20. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
Sikavi C; Najarian L; Saab S
Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]